Pyxis Oncology, Inc.

Pyxis Oncology, Inc. is a U.S.-based clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates and related oncology therapeutics. The company’s work centers on advancing cancer drug candidates through preclinical and clinical development and, where applicable, partnering for development and commercialization in selected markets.

−576,6 %

82,8 %

−574,5 %

−14,2 %

3.41

3.41

— Pyxis Oncology, Inc.
%
Oncology drug candidates0% Clinical and preclinical cancer therapeutics, including ADC-based programs.
Collaboration and milestone revenue100% Revenue from licensing, development milestones, and partner agreements.
Research and development services0% Internal and partnered R&D activities supporting pipeline advancement.

Pyxis Oncology’s direct commercial customers are limited because its product candidates are still in development...

  • Pharmaceutical collaboration partnersprimary

    Partners such as Simcere that pay milestones and support development/commercialization in defined territories.

  • Healthcare providers and oncologistsprimary

    Physicians who would prescribe approved oncology products and influence adoption.

  • Third-party payorssecondary

    Insurers and reimbursement bodies that determine patient access and pricing economics.

  • Wholesalers and distributorssecondary

    Channel partners that would handle product distribution if the company commercializes indirectly.

  • Research institutions and CROssecondary

    Clinical trial sites and contract research organizations that execute development work.

Pyxis Oncology is headquartered in the United States and conducts its core corporate and development activities from...

  • •Headquartered in the United States
  • •Core R&D and corporate functions are U.S.-based
  • •China is a disclosed partner market through Simcere
  • •Future commercialization may require country-specific infrastructure
  • •Geography matters because approvals and payor rules are local

The company’s strategy is centered on advancing oncology candidates through research, preclinical work, and clinical...

01
Advance the oncology pipelinemedium-term

Clinical progress is the main driver of value creation for a development-stage biotech.

02
Partner for selected geographiesmedium-term

Out-licensing can reduce commercialization burden and provide milestone economics.

03
Protect intellectual propertylong-term

Patent and know-how protection support exclusivity and partnering leverage.

04
Prepare for future commercializationmedium-term

Approved products require sales, marketing, and distribution capabilities or partners.

Pyxis Oncology faces the typical risks of a clinical-stage biotech: development failure, regulatory uncertainty, and...

critical

Clinical development failure

Pipeline value depends on successful preclinical and clinical outcomes, which are uncertain.

Scope
All product candidates
Materiality
high
high

Need for additional capital

The company has no approved products and continues to fund R&D and trials.

Scope
Corporate funding and pipeline execution
Materiality
high
high

Commercialization dependence on partners

If it outsources sales or relies on collaborators, execution and economics are partly outside its control.

Scope
Future approved products and ex-U.S. markets
Materiality
high
high

Regulatory and healthcare compliance

Drug promotion, pricing, and relationships with providers/payors are governed by strict laws.

Scope
U.S. and international commercialization
Materiality
medium
high

Competitive pressure in oncology

Many ADC and immunotherapy programs compete for the same indications and capital.

Scope
Pipeline differentiation and partnering leverage
Materiality
high
medium

Cybersecurity and data handling

Clinical, proprietary, and personal data are stored across internal and third-party systems.

Scope
R&D operations and collaborator networks
Materiality
medium
Milestone and collaboration revenue recognition
Quarterly revenue can swing materially based on partner events
Research and development expense
Directly drives operating losses and cash burn
Stock-based compensation
Can materially increase reported G&A and R&D expense
Intangible assets and contract rights
May affect cost of revenues and non-cash charges

Compass Therapeutics, Inc.

CMPX · Biological Products, (No Diagnostic Substances)

PRECIGEN, INC.

PGEN · Pharmaceutical Preparations

GENELUX Corp

GNLX · Pharmaceutical Preparations

Vincerx Pharma, Inc.

Pharmaceutical Preparations

Oric Pharmaceuticals, Inc.

ORIC · Pharmaceutical Preparations

PDS Biotechnology Corp

PDSB · Pharmaceutical Preparations

: 29/04/2026